Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Company Deals

Menarini Group Expands Oncology Pipeline with Insilico Medicine License

Fineline Cube Jan 13, 2025

Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal...

Company Deals

Zai Lab Secures Rights to Vertex’s Povetacicept in Key Asian Markets

Fineline Cube Jan 13, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced an exclusive collaboration and...

Company Deals

Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion

Fineline Cube Jan 13, 2025

US-based Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks with compatriot firm...

Company Deals

Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development

Fineline Cube Jan 13, 2025

US-based Light Horse Therapeutics Inc., a small molecule drug developer that recently emerged from the...

Company Deals

Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market

Fineline Cube Jan 13, 2025

South Korea’s Samsung Bioepis and Israel-based Teva Pharmaceutical (NYSE: TEVA) have entered into a license,...

Company Deals

Sepax Technologies Debuts on STAR Market with Soaring IPO Prices

Fineline Cube Jan 13, 2025

Sino-US firm Sepax Technologies Co., Inc. has successfully completed its initial public offering (IPO) on...

Company Drug

Bayer Files for Finerenone Approval in US and China for Heart Failure-Fineline Info & Tech

Fineline Cube Jan 13, 2025

Bayer AG (ETR: BAYN) has announced market filings with the US Food and Drug Administration...

Company Drug

Pfizer’s Sasanlimab Shows Positive Results in Phase III CREST Study

Fineline Cube Jan 13, 2025

US-based Pfizer Inc. (NYSE: PFE) has reported positive topline results from its pivotal Phase III...

Company Drug

NMPA Approves J&J’s FGFR Kinase Inhibitor Balversa for Urothelial Carcinoma

Fineline Cube Jan 13, 2025

China’s National Medical Products Administration (NMPA) has approved Johnson & Johnson’s (J&J; NYSE: JNJ) FGFR...

Company Drug

Doma Biopharma Receives FDA Clearance for DM002 Phase I Study-Fineline Info & Tech

Fineline Cube Jan 13, 2025

China-based Doma Biopharmaceutical (Suzhou) Co., Ltd has announced that it has received clearance from the...

Company Drug

GSK’s Shingrix Prefilled Syringe Accepted for FDA Review

Fineline Cube Jan 13, 2025

UK-headquartered GlaxoSmithKline (GSK; NYSE: GSK) has announced that a market filing for a prefilled syringe...

Policy / Regulatory

NHSA Launches Nationwide Self-Inspection Campaign on Medical Insurance Fund Usage

Fineline Cube Jan 13, 2025

China’s National Healthcare Security Administration (NHSA) released a notification last weekend, mandating designated medical institutions...

Policy / Regulatory

China’s NHSA Implements New Regulations for Medical Insurance Payment Qualifications

Fineline Cube Jan 13, 2025

China’s National Healthcare Security Administration (NHSA) has released the “Regulations on the Management of Medical...

Company

Shenzhen Oculgen Secures Over RMB 100 Million in Series A Funding

Fineline Cube Jan 11, 2025

Shenzhen Oculgen Biomedical Technology Co., Ltd. has successfully completed a Series A financing round, raising...

Company Drug

Fosun Pharmaceutical’s FCN-437c Accepted for NMPA Review for Breast Cancer Treatment

Fineline Cube Jan 11, 2025

Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has announced that another market approval...

Company Drug

Hengrui’s SHR4640 Accepted for NMPA Review for Gout and Hyperuricemia Treatment

Fineline Cube Jan 11, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that a market filing for...

Company Deals

Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development

Fineline Cube Jan 11, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm...

Company Deals

Biocytogen and SOTIO Biotech Partner on Colorectal Cancer ADC Candidate SOT109

Fineline Cube Jan 11, 2025

China-based Biocytogen (HKG: 2315) has announced an option and licensing agreement with SOTIO Biotech, allowing...

Company Deals

Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes

Fineline Cube Jan 11, 2025

Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to...

Company Deals

Immunochina Pharmaceuticals Raises Series E Funding for CAR-T Therapy IM19

Fineline Cube Jan 11, 2025

Beijing-based biotech Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series...

Posts pagination

1 … 165 166 167 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.